Relmada Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Relmada Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Relmada Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Relmada Therapeutics Inc. is RLMD:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Relmada Therapeutics Inc. has its primary listing on NASDAQ (Small cap). You can trade Relmada Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Relmada Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Relmada Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Relmada Therapeutics Inc..